Compare Boston Scientific Corporation (BSX) vs MasterCard Inc (MA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs MasterCard Inc — how do they compare? Boston Scientific Corporation trades at $42.73 (market cap $66.37B), while MasterCard Inc trades at $539.25 (market cap $475.39B). The key difference: MasterCard Inc is far larger — about 7.2× Boston Scientific Corporation's market cap, and MasterCard Inc pays a 0.65% dividend while Boston Scientific Corporation pays none. Which is the better fit depends on your goals.
| BSX | MA | |
|---|---|---|
Market Cap | $66.37B | $475.39B |
Sector | Health | Consumer Cyclical |
52-Week High | $108.14 | $598.96 |
52-Week Low | $42.63 | $471.55 |
Enterprise Value | $75.94B | $486.13B |
Volume | — | 4,635,698 |
Dividend Yield | — | 0.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $44.65, down 0.27% with bearish technical signals despite strong fundamentals. The company delivered three consecutive earnings beats with Q3-Q1 2026 EPS exceeding expectations, while revenue grew to $20.07B in 2025 with improving profit margins. Technical indicators show bearish momentum with support at $44 and resistance at $45, though Wall Street maintains 88% buy rating with $70.20 consensus target.
BSX presents a compelling value opportunity with attractive valuation multiples (P/E 18.68, P/S 3.24) and robust financial health, though near-term headwinds include competitive pressures in key segments and recent stock price decline of nearly 60% from 2025 highs. The strong analyst consensus suggests significant upside potential if execution improves.
Mastercard (MA) trades at $537.70, up 2.08% today, with a bullish technical outlook and strong fundamentals. The stock shows consistent earnings beats, with Q1 2026 EPS of $4.60 exceeding the $4.41 estimate. Revenue grew to $32.79B in 2025, and net income margin remains robust at 45.88%. Analysts maintain a strong buy consensus, with a price target of $634.27, indicating ~18% upside. Recent news highlights institutional accumulation and AI-driven payment innovations.
The outlook for MA is positive, driven by earnings momentum and strategic expansion into digital payments. Key risks include competitive disruption from stablecoins and regulatory scrutiny. With high profitability and institutional support, the stock presents a growth opportunity, though investors should monitor payment industry evolution and macroeconomic factors affecting consumer spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About MasterCard Inc
Mastercard Incorporated provides financial transaction processing services. The Company offers payment processing services for credit and debit cards, electronic cash, automated teller machines, and travelers checks. Mastercard serves customers worldwide.
Read more on MA →
